<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221220056877N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-25</date_registration>
      <primary_sponsor>University of Baghdad</primary_sponsor>
      <public_title>Effectiveness of Foot Bathing, Massage, and Range of Motion Exercise on patients with Diabetic Peripheral Neuropathy: A Clinical Trial</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of Foot Bathing, Massage, and Range of Motion Exercise on Diabetic Patients' Peripheral Neuropathy: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67523</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: In order to maintain a transparent and scientifically based randomization process, stratified randomization will be used in assigning participants (individuals: diabetic patients with peripheral neuropathy) to intervention (foot bathing, foot massage, and range of motion exercise) and control groups, assuming that each participant has an equal chance of being assigned to any group. The simple randomization procedure would involve choosing a color from a sealed envelope that contains four numbers: blue, yellow, green, and red (blue would be in the foot bathing group, yellow would be in the foot massage group, green would be in the range of motion exercises group, and red would be in the control group). Indeed, four groups will be allocated randomly.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diabetes Mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After assessing the level of diabetic peripheral neuropathy, the sample will be allocated into four groups: the foot bathing group, which involves immersing both patients' feet in 5 liters of tolerably warm water (between 40 and 45 °C) with 250 grams of powdered mineral salt added and dissolved; the foot massage group, in which the researcher's thumb is used to apply gentle, gradually increasing pressure along the three meridians lines on the feet. Pressure is also applied to the area of the knee in the supine and side-lying positions and to the lower leg, ankle, and foot of the participants. The range-of-motion exercise group combined ROM with plantar exercise and placed a tennis ball for 30 minutes every two days. The active ROM procedure covered flexion-extension-adduction-abduction in the hips and toes, flexion-extension of the knees, dorsiflexion and plantar flexion in the ankles, and inversion-eversion of the legs. Place a tennis ball on the ground and ask patients to gently roll it underfoot, backward and forward, and rotate it along the plantar for five minutes to relax the muscles in the plantar fascia. Then patients in all groups were evaluated prior to the intervention (post-test assessment) after two weeks by using the Toronto Clinical Neuropathy Score. Intervention 2: Control group: The control group received no interventions; instead, they received pre-test and post-test assessments after two weeks, as did the other groups, and they will be compared to the other groups in the study. Then patients in all groups were evaluated prior to the intervention (post-test assessment) after two weeks by using the TCNS.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be the results of the TCNS that measure patients' DPN levels in both the control and intervention groups.

When:
God Willing, once the article is published, the data will be available after 6 months of publication. If the article will be published in a subscribed journal, the data will be available after one year because of the policy of the subscribed journals.

To whom:
with academic nurses and any researcher who is interested in the data.

Conditions:
The data could be used after getting permission via email. Also, users need to acknowledge the owner.

Where to obtain:
Users can ask for the data and permission via email. Taher Al-Fahham is the corresponding author. He will contact whoever he requests the information from. His email is taher.m@uokerbala.edu.iq 
Taher Al-Fahham works at the University of Kerbala/College of Nursing. The address is Al-Muadhafeen district, Karbala, Iraq. What processes are involved for a request to access data/document

How to obtain:
Users can ask for the data and permission via email. Taher Al-Fahham is the corresponding author. He will contact whoever he requests the information from. His email is taher.m@uokerbala.edu.iq

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Taher Mohsin Hashim Al-Fahham</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Baladia district</address>
        <city>Karbala</city>
        <country1>Iraq</country1>
        <zip>56001</zip>
        <telephone>+964 783 906 5883</telephone>
        <email>taher.m@uokerbala.edu.iq</email>
        <affiliation>University of Kerbala</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Taher Mohsin Hashim Al-Fahham</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Baladia distric</address>
        <city>Karbala</city>
        <country1>Iraq</country1>
        <zip>56001</zip>
        <telephone>+964 783 906 5883</telephone>
        <email>taher.m@uokerbala.edu.iq</email>
        <affiliation>University of Kerbala</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are more than or equal to 18 years old
Patients who have been diagnosed with diabetes for 10 years and more
Patients who have Diabetic Peripheral Neuropathy (DPN) of more than 5 on Toronto Clinical neuropathy score (TCNS)
Patients with Type-1 and Type-2 Diabetes Mellitus</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with score of 5 and less than in TCNS scale
Patients who have Chemotherapy-Induced Peripheral Neuropathy
Patients with foot gangrene
Patients with amputated right or left foot
Patients who refused to participate in the study
Patients with paralysis, partly or entirely unable to move the affected parts of the body
patients with osteoarthritis and osteomyelitis, rheumatoid arthritis
Patient with certain viral or bacterial infections, including Lyme disease, shingles, Epstein-Barr virus, hepatitis B and C, leprosy, Diphtheria, and HIV)
Patients who are receiving any physiotherapy intervention
Patients with inherited disorders, such as Charcot-Marie-Tooth disease are hereditary types of neuropathy;
Patients with autoimmune diseases, include lupus, Guillain-Barre syndrome, demyelinating polyneuropathy and vasculitis
Patients with bone marrow disorders, These include Multiple myeloma, lymphoma and amyloidosis
Patients with other diseases, include kidney and liver disease, connective tissue disorders and hypothyroidism)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G90.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Idiopathic peripheral autonomic neuropathy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After assessing the level of diabetic peripheral neuropathy, the sample will be allocated into four groups: the foot bathing group, which involves immersing both patients' feet in 5 liters of tolerably warm water (between 40 and 45 °C) with 250 grams of powdered mineral salt added and dissolved; the foot massage group, in which the researcher's thumb is used to apply gentle, gradually increasing pressure along the three meridians lines on the feet. Pressure is also applied to the area of the knee in the supine and side-lying positions and to the lower leg, ankle, and foot of the participants. The range-of-motion exercise group combined ROM with plantar exercise and placed a tennis ball for 30 minutes every two days. The active ROM procedure covered flexion-extension-adduction-abduction in the hips and toes, flexion-extension of the knees, dorsiflexion and plantar flexion in the ankles, and inversion-eversion of the legs. Place a tennis ball on the ground and ask patients to gently roll it underfoot, backward and forward, and rotate it along the plantar for five minutes to relax the muscles in the plantar fascia. Then patients in all groups were evaluated prior to the intervention (post-test assessment) after two weeks by using the Toronto Clinical Neuropathy Score.</i_keyword>
      <i_keyword>Control group: The control group received no interventions; instead, they received pre-test and post-test assessments after two weeks, as did the other groups, and they will be compared to the other groups in the study. Then patients in all groups were evaluated prior to the intervention (post-test assessment) after two weeks by using the TCNS.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome variable is the level of Diabetic Peripheral Neuropathy that can be changed based on foot bathing, foot massage, and ROM exercises. Timepoint: Before intervention and two weeks after intervention. Method of measurement: The Toronto Clinical Neuropathy Score will be used to assess the level of DPN.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The author of the trial is the funding source</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-19</approval_date>
        <contact_name>Ethics committee in College of Nursing at University of Baghdad</contact_name>
        <contact_address>Bab-AlMuadham Baghdad Baghdad Iraq</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
